dipolar compound - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	dipolar compound	go back to main search page
Accession:	CHEBI:51151	browse the term
Definition:	An organic molecule that is electrically neutral carrying a positive and a negative charge in one of its major canonical descriptions. In most dipolar compounds the charges are delocalized; however the term is also applied to species where this is not the case.
Synonyms:	related_synonym:	dipolar compounds

show annotations for term's descendants Sort by:
Rat (462) Mouse (471) Human (464) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (35) Green Monkey (0) Naked Mole-rat (0) All
Genes (462)

(R)-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

decreases expression

Carnitine results in decreased expression of ACACA protein

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

decreases expression

Carnitine results in decreased expression of ACACB protein

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

adiponectin, C1Q and collagen domain containing

increases expression

Carnitine results in increased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions

Carnitine results in decreased expression of BAX protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein]

PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

gamma-butyrobetaine hydroxylase 1

multiple interactions
increases chemical synthesis

Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

BCL2, apoptosis regulator

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]

PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

caspase 3

multiple interactions
increases expression

Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]
Carnitine results in increased expression of CASP3 protein
Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein]

PMID:19491382 PMID:23213347 PMID:25669660 PMID:26562095 PMID:32478940 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA]
Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein]

PMID:23213347 PMID:32478940

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]

PMID:16889571 PMID:19294768 PMID:23213347

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cadherin 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

collagen type I alpha 1 chain

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA]

PMID:26581635 PMID:28973641

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

carnitine palmitoyltransferase 1A

multiple interactions

valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine]
[Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein]

PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 2

multiple interactions
increases expression

Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]
Carnitine results in increased expression of CPT2 protein

PMID:21816645 PMID:25669660

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

cytochrome b-245 beta chain

multiple interactions

Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

fatty acid binding protein 3

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA]

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

fatty acid binding protein 9

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]

NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873

G

fatty acid synthase

decreases expression

Carnitine results in decreased expression of FASN protein

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

follicle stimulating hormone subunit beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

growth differentiation factor 9

multiple interactions
increases expression

Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA]
Carnitine results in increased expression of GDF9 mRNA

NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672

G

glial fibrillary acidic protein

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gap junction protein, alpha 1

multiple interactions
increases expression

Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA]
Carnitine results in increased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, alpha 4

increases expression
multiple interactions

Carnitine results in increased expression of GJA4 mRNA
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA]

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

glutamic--pyruvic transaminase

multiple interactions

Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA]

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

multiple interactions

Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein]

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

hyaluronan synthase 2

multiple interactions
increases expression

Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA]
Carnitine results in increased expression of HAS2 mRNA

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

heme oxygenase 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

harakiri, BCL2 interacting protein

multiple interactions

Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein]

NCBI chr12:38,387,484...38,409,652

G

heat shock protein family A (Hsp70) member 2

multiple interactions

Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein]

NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 10

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA]

PMID:26581635 PMID:33965443

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

increases expression

Carnitine results in increased expression of IL18 protein

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions
increases expression

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA]
Carnitine results in increased expression of IL1B protein

PMID:25669660 PMID:26562095 PMID:26581635

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA]

PMID:26581635 PMID:33965443 PMID:37312617

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

decreases uptake
multiple interactions

INS1 protein results in decreased uptake of Carnitine
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein]

PMID:28298333 PMID:30256492

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

lactate dehydrogenase A

multiple interactions

Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein]

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

leptin receptor

affects abundance

LEPR affects the abundance of Carnitine

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

luteinizing hormone subunit beta

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

matrix metallopeptidase 9

multiple interactions

Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions
increases activity

[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein]

PMID:18597074 PMID:18852009

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

multiple interactions

Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

microsomal triglyceride transfer protein

multiple interactions

Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

NFE2 like bZIP transcription factor 2

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

increases expression

Carnitine results in increased expression of NLRP3 protein

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]

PMID:23213347 PMID:33965443

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression

Carnitine results in increased expression of NOS3

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

occludin

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

peroxisome proliferator activated receptor alpha

multiple interactions
increases expression
increases activity

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins]
Carnitine results in increased expression of PPARA protein
Carnitine results in increased activity of PPARA protein

PMID:19491382 PMID:19735737 PMID:25669660

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

increases expression
multiple interactions

Carnitine results in increased expression of PPARG protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prostaglandin I2 synthase

increases expression
increases response to substance
multiple interactions

Carnitine results in increased expression of PTGIS mRNA
PTGIS protein results in increased susceptibility to Carnitine
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha

NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451

G

PYD and CARD domain containing

increases expression

Carnitine results in increased expression of PYCARD protein

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

stearoyl-CoA desaturase

decreases expression

Carnitine results in decreased expression of SCD protein

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sirtuin 1

multiple interactions

Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 3

multiple interactions

Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA]

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

solute carrier family 22 member 1

decreases expression

Carnitine results in decreased expression of SLC22A1 protein

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

decreases expression

Carnitine results in decreased expression of SLC22A2 protein

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 22 (organic cation transporter), member 21

multiple interactions
increases uptake

[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]

NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671

G

solute carrier family 22 member 4

increases uptake
decreases expression

SLC22A4 protein results in increased uptake of Carnitine
Carnitine results in decreased expression of SLC22A4 protein

PMID:21256917 PMID:25669660 PMID:33007874

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

solute carrier family 22 member 5

multiple interactions
affects expression
decreases expression
increases transport
increases uptake
increases expression
affects uptake
affects binding

[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine affects the expression of SLC22A5 protein
Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin]
Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]
Carnitine deficiency results in increased expression of SLC22A5 mRNA
SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog
SLC22A5 protein affects the uptake of Carnitine
Carnitine binds to SLC22A5 protein

PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 More...

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 22 member 8

increases transport

SLC22A8 protein results in increased transport of Carnitine

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25 member 20

multiple interactions
increases transport

Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]

PMID:18452908 PMID:23402788

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 2 member 4

increases expression
multiple interactions

Carnitine results in increased expression of SLC2A4 protein
Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

snail family transcriptional repressor 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression

Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA]
Carnitine results in decreased expression of SREBF1 protein

PMID:18299183 PMID:25669660

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

steroidogenic acute regulatory protein

multiple interactions

Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

transforming growth factor, beta 1

multiple interactions

Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA]

PMID:26562095 PMID:26581635 PMID:28973641

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tight junction protein 1

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

increases expression
multiple interactions
decreases expression

Carnitine deficiency results in increased expression of TNF mRNA
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein]
Carnitine results in decreased expression of TNF protein

PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vimentin

multiple interactions

Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

1,2-dihexadecanoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 6

multiple interactions

1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

prion protein

multiple interactions
affects folding

Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form]

NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937

1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ferrochelatase

affects abundance

FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

1-O-oleoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

SMAD family member 3

decreases abundance

SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

arachidonate 5-lipoxygenase

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine receptor 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

Cd68 molecule

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

C-reactive protein

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

gap junction protein, alpha 1

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

interleukin 1 alpha

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium voltage-gated channel subfamily A regulatory beta subunit 2

multiple interactions

[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine

NCBI chr 5:162,899,511...162,988,057
Ensembl chr 5:162,901,896...162,988,243

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

oxidized low density lipoprotein receptor 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

platelet-activating factor receptor

affects binding
multiple interactions

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin E

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions
increases phosphorylation

resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

TIMP metallopeptidase inhibitor 4

increases expression

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

tumor necrosis factor

increases expression
increases secretion

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase G, endothelial type

increases hydrolysis

LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

1-stearoyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

lipase C, hepatic type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipase G, endothelial type

multiple interactions

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

2-acetyl-1-alkyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin II receptor, type 1a

increases expression

Platelet Activating Factor results in increased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

arachidonate 12-lipoxygenase, 12S type

increases expression

Platelet Activating Factor results in increased expression of ALOX12 mRNA

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 5-lipoxygenase

multiple interactions
increases expression

[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor]
Platelet Activating Factor results in increased expression of ALOX5 mRNA

PMID:8387780 PMID:10779545 PMID:16386258

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine ligand 2

multiple interactions
increases secretion

Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine receptor 2

increases expression

Platelet Activating Factor results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-reactive protein

increases expression

Platelet Activating Factor results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

C-X3-C motif chemokine receptor 1

increases expression

Platelet Activating Factor results in increased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

endothelin 1

multiple interactions
increases abundance

Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin receptor type B

multiple interactions

EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

early growth response 1

increases expression

Platelet Activating Factor results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

glucuronidase, beta

multiple interactions

[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

interleukin 1 alpha

increases expression

Platelet Activating Factor results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression
increases secretion
multiple interactions

Platelet Activating Factor results in increased expression of IL1B mRNA
Platelet Activating Factor results in increased secretion of IL1B protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]

PMID:16386258 PMID:32830409

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases secretion

[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]

PMID:9762784 PMID:11116075

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

leukotriene B4 receptor

affects response to substance

LTB4R1 protein affects the susceptibility to Platelet Activating Factor

NCBI chr15:29,263,199...29,265,716

G

matrix metallopeptidase 13

increases expression

Platelet Activating Factor results in increased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

MYD88, innate immune signal transduction adaptor

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of MYD88 protein
PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

neutral cholesterol ester hydrolase 1

multiple interactions

NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:110,074,957...110,135,588

G

NFKB inhibitor alpha

multiple interactions
increases degradation

Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

oxidized low density lipoprotein receptor 1

increases expression

Platelet Activating Factor results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

phospholipase A2 group VII

multiple interactions
increases expression

[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA]

NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476

G

peroxisome proliferator activated receptor alpha

decreases expression

Platelet Activating Factor results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

platelet-activating factor receptor

multiple interactions
increases expression
increases phosphorylation
affects binding

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
Platelet Activating Factor results in increased expression of PTAFR mRNA
Platelet Activating Factor results in increased phosphorylation of PTAFR protein
bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]

PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 More...

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

increases expression

Platelet Activating Factor results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

increases expression

Platelet Activating Factor results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

Pvt1 oncogene

increases expression
multiple interactions

Platelet Activating Factor results in increased expression of PVT1 mRNA
[Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]

NCBI chr 7:93,656,528...93,879,938

G

regulator of G-protein signaling 4

multiple interactions

RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

selectin E

increases expression

Platelet Activating Factor results in increased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selectin L

multiple interactions
increases secretion

Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

selectin P

multiple interactions
increases expression

Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein]

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

TIMP metallopeptidase inhibitor 4

increases expression

Platelet Activating Factor results in increased expression of TIMP4 mRNA

NCBI chr 4:148,306,021...148,312,558
Ensembl chr 4:148,304,490...148,312,558

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

Platelet Activating Factor results in increased secretion of TNF protein
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
Platelet Activating Factor results in increased expression of TNF mRNA
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]

PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma

RGD

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

3-dehydrocarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

4-(trimethylammonio)butanoate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-butyrobetaine hydroxylase 1

multiple interactions

[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

5,5-dimethyl-1-pyrroline N-oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

albumin

multiple interactions

[NOS1 co-treated with sodium sulfite co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased oxidation of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

myeloperoxidase

multiple interactions

4'-hydroxydiclofenac promotes the reaction [[Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide]; [[Hydrogen Peroxide results in increased activity of MPO protein] which results in increased oxidation of Glutathione] which results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-anisidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-anisidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-aminobenzonitrile] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-ethylaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of aniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Procainamide] which results in increased expression of MPO protein modified form; [Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-anisidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-anisidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-aminobenzonitrile; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-ethylaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of aniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Procainamide; desmethylnaproxen promotes the reaction [[Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide]

PMID:20199096 PMID:28754375

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 1

multiple interactions

[NOS1 co-treated with sodium sulfite co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased oxidation of ALB protein

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

CAR(3:0(Me2))

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 5

affects binding
increases uptake
multiple interactions
increases transport

pivaloylcarnitine binds to SLC22A5 protein
SLC22A5 protein results in increased uptake of pivaloylcarnitine
Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]

PMID:18762717 PMID:19539806

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase beta

decreases expression

L-carnitine decreases expression of Acacb mRNA and protein in rat heart

RGD

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

carnitine palmitoyltransferase 1A

increases expression
multiple interactions

L-carnitine increases expression of Cpt1a mRNA and protein in rat heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

malonyl-CoA decarboxylase

increases expression
multiple interactions

L-carnitine increases expression of Mlycd protein in rat heart
L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression
multiple interactions

L-carnitine increases expression of Ampka2 protein in rat serum and heart
L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart]

RGD

PMID:30644033 PMID:30644033

RGD:329955369, RGD:329955369

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

ceftaroline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

defensin beta 5

multiple interactions

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein]

PMID:27397760 PMID:28720485

NCBI chr16:70,612,985...70,615,389
Ensembl chr16:70,613,146...70,615,467

G

interleukin 1 beta

multiple interactions

Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

toll-like receptor 2

multiple interactions

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

ergothioneine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Ergothioneine inhibits the reaction [Cisplatin results in decreased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

AKT serine/threonine kinase 1

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

caspase 3

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glutamic--pyruvic transaminase

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 6

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 22 member 4

multiple interactions

Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of and results in increased localization of Doxorubicin]
Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of Doxorubicin]

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

tumor necrosis factor

multiple interactions

Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

glycine betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ABI family member 3 binding protein

increases expression

Betaine results in increased expression of ABI3BP mRNA

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

acetyl-CoA carboxylase alpha

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetyl-CoA carboxylase beta

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein]

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin alpha 2, smooth muscle

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of ACTA2 mRNA]

PMID:37840533 PMID:38651543

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adhesion G protein-coupled receptor G2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA

NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609

G

adenylosuccinate synthase 2

decreases expression

Betaine results in decreased expression of ADSS2 mRNA

NCBI chr13:89,769,240...89,799,577
Ensembl chr13:89,769,244...89,799,604

G

adenosylhomocysteinase

decreases expression

Betaine results in decreased expression of AHCY mRNA

PMID:22945834 PMID:26391144

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

A-kinase interacting protein 1

increases expression

Betaine results in increased expression of AKIP1 mRNA

NCBI chr 1:163,734,730...163,743,648
Ensembl chr 1:163,734,798...163,743,648

G

aldo-keto reductase family 1 member B1

decreases expression

Betaine results in decreased expression of AKR1B1 mRNA

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1, member B7

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA

NCBI chr 4:63,053,560...63,100,934
Ensembl chr 4:63,076,800...63,089,502

G

albumin

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 2 family member

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

apurinic/apyrimidinic endodeoxyribonuclease 1

decreases expression

Betaine results in decreased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

amyloid beta precursor protein

multiple interactions

Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

ATPase copper transporting beta

multiple interactions

ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

axin 1

multiple interactions

[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene

NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615

G

BCL2 associated X, apoptosis regulator

decreases expression

Betaine results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

affects binding
increases expression

Betaine analog binds to BCL2 protein
Betaine results in increased expression of BCL2 protein

PMID:25080425 PMID:25765238

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix family, member e40

increases expression

Betaine results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

betaine-homocysteine S-methyltransferase

increases metabolic processing

BHMT protein results in increased metabolism of Betaine

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

BRF1 general transcription factor IIIB subunit

multiple interactions

Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein]

NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278

G

calcium binding protein 39-like

decreases expression

Betaine results in decreased expression of CAB39L mRNA

NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545

G

caspase 1

increases expression

Betaine results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein; Betaine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]
Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein]; Betaine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]

PMID:12893363 PMID:20118189 PMID:24632105 PMID:36087182 PMID:37840533 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 113

increases expression

Betaine results in increased expression of CCDC113 mRNA

NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923

G

C-C motif chemokine ligand 2

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

increases expression

Betaine results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 9

increases expression

Betaine results in increased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

cyclin B2

decreases expression

Betaine results in decreased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

CD44 molecule

decreases expression

Betaine results in decreased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CDC42 effector protein 2

decreases expression

Betaine results in decreased expression of CDC42EP2 mRNA

NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897

G

cadherin 13

decreases expression

Betaine results in decreased expression of CDH13 mRNA

NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459

G

cyclin-dependent kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 2A

multiple interactions

Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA]

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

carboxylesterase 2C

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 3a

increases expression

Betaine results in increased expression of CES3 mRNA

NCBI chr19:32,992,386...33,000,562

G

creatine kinase B

increases expression

Betaine results in increased expression of CKB mRNA

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

CDC28 protein kinase regulatory subunit 1B

decreases expression

Betaine results in decreased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

cardiotrophin-like cytokine factor 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

coactosin-like F-actin binding protein 1

decreases expression

Betaine results in decreased expression of COTL1 mRNA

NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689

G

carnitine palmitoyltransferase 1A

multiple interactions
decreases expression

Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in decreased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

C-X-C motif chemokine ligand 16

decreases expression

Betaine results in decreased expression of CXCL16 mRNA

NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 24

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]
Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1]

PMID:20118189 PMID:21352821

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cysteinyl leukotriene receptor 1

increases expression

Betaine results in increased expression of CYSLTR1 mRNA

NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121

G

death associated protein kinase 1

decreases expression

Betaine results in decreased expression of DAPK1 mRNA

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

DEPP autophagy regulator 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

distal-less homeobox 2

increases expression

Betaine results in increased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

DNA methyltransferase 1

multiple interactions
increases expression

Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in increased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 beta

decreases expression

Betaine results in decreased expression of DNMT3B mRNA

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

E2F transcription factor 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

epithelial cell transforming 2

decreases expression

Betaine results in decreased expression of ECT2 mRNA

NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911

G

eukaryotic elongation factor-2 kinase

increases expression

Betaine results in increased expression of EEF2K mRNA

NCBI chr 1:175,393,119...175,456,756
Ensembl chr 1:175,393,154...175,455,164

G

epidermal growth factor receptor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

increases expression
multiple interactions

Betaine results in increased expression of EGR1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA

PMID:26391144 PMID:33549593

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

E74 like ETS transcription factor 3

decreases expression

Betaine results in decreased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

ER membrane protein complex subunit 9

increases expression

Betaine results in increased expression of EMC9 mRNA

NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098

G

Eph receptor B6

increases expression

Betaine results in increased expression of EPHB6 mRNA

NCBI chr 4:70,491,973...70,507,230
Ensembl chr 4:70,491,973...70,507,230

G

establishment of sister chromatid cohesion N-acetyltransferase 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA

NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306

G

coagulation factor VIII

multiple interactions
increases secretion

Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form
Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form

NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857

G

coagulation factor IX

increases secretion

Betaine results in increased secretion of F9 protein

NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835

G

fatty acid binding protein 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

fatty acid synthase

multiple interactions

[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibronectin leucine rich transmembrane protein 3

increases expression

Betaine results in increased expression of FLRT3 mRNA

NCBI chr 3:127,994,491...128,008,137
Ensembl chr 3:127,994,226...128,007,841

G

FXYD domain-containing ion transport regulator 2

decreases expression

Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form

NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

galanin and GMAP prepropeptide

multiple interactions

Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein]

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

glucokinase

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

G protein subunit alpha 14

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA

NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423

G

glycerophosphocholine phosphodiesterase 1

increases expression
multiple interactions

Betaine results in increased expression of GPCPD1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA

PMID:26391144 PMID:33549593

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

glutamic--pyruvic transaminase

multiple interactions

Betaine inhibits the reaction [sodium arsenite results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

Betaine inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutathione S-transferase alpha 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase, mu 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glucuronidase, beta

multiple interactions

Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein]

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

H2A.Z variant histone 1

decreases expression

Betaine results in decreased expression of H2AZ1 mRNA

NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485

G

huntingtin interacting protein 1

decreases expression

Betaine results in decreased expression of HIP1 mRNA

NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725

G

high mobility group box 2

decreases expression

Betaine results in decreased expression of HMGB2 mRNA

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
Ensembl chr 1:32,710,658...32,713,140

G

heme oxygenase 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

decreases expression

Betaine results in decreased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

inhibitor of DNA binding 2

increases expression

Betaine results in increased expression of ID2 mRNA

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Betaine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 6

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]

PMID:37840533 PMID:38651543

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin receptor substrate 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

iroquois homeobox 4

decreases expression

Betaine results in decreased expression of IRX4 mRNA

NCBI chr 1:30,030,561...30,039,549
Ensembl chr 1:30,030,561...30,039,549

G

integrin subunit alpha 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA

NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510

G

integrin subunit beta 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Betaine results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

KH RNA binding domain containing, signal transduction associated 3

decreases expression

Betaine results in decreased expression of KHDRBS3 mRNA

NCBI chr 7:100,837,707...100,995,644
Ensembl chr 7:100,837,934...100,988,460

G

kinesin family member 1B

increases expression

Betaine results in increased expression of KIF1B mRNA

NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778

G

kinesin family member 22

decreases expression

Betaine results in decreased expression of KIF22 mRNA

NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401

G

KLF transcription factor 10

increases expression

Betaine results in increased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

keratin 2

increases expression

Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein

NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963

G

keratin 4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA

NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019

G

leucyl-tRNA synthetase 1

decreases expression

Betaine results in decreased expression of LARS1 mRNA

NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931

G

leptin receptor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

lin-9 DREAM MuvB core complex component

decreases expression

Betaine results in decreased expression of LIN9 mRNA

NCBI chr13:92,374,612...92,419,664
Ensembl chr13:92,374,593...92,419,654
Ensembl chr14:92,374,593...92,419,654

G

LRAT domain containing 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA

NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319

G

leucine rich repeat containing 24

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA

NCBI chr 7:108,437,296...108,444,561
Ensembl chr 7:108,437,296...108,444,438

G

mitogen activated protein kinase kinase kinase kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA

NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493

G

membrane associated ring-CH-type finger 6

multiple interactions
decreases stability

Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]

NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910

G

minichromosome maintenance complex component 3

decreases expression

Betaine results in decreased expression of MCM3 mRNA

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314

G

minichromosome maintenance complex component 4

decreases expression

Betaine results in decreased expression of MCM4 mRNA

NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144

G

minichromosome maintenance complex component 5

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA

NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389

G

minichromosome maintenance complex component 6

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

decreases expression

Betaine results in decreased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

microtubule associated monooxygenase, calponin and LIM domain containing 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA

NCBI chr20:44,974,137...44,986,089
Ensembl chr20:44,974,138...44,986,089

G

marker of proliferation Ki-67

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

decreases expression

Betaine results in decreased expression of MTHFD1L mRNA

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

Betaine results in decreased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

MYCL proto-oncogene, bHLH transcription factor

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA

NCBI chr 5:135,274,713...135,281,584
Ensembl chr 5:135,274,748...135,281,582

G

NBL1, DAN family BMP antagonist

increases expression

Betaine results in increased expression of NBL1 mRNA

NCBI chr 5:151,318,752...151,329,948
Ensembl chr 5:151,318,754...151,338,719

G

NCK interacting protein with SH3 domain

decreases expression

Betaine results in decreased expression of NCKIPSD mRNA

NCBI chr 8:109,511,484...109,522,622
Ensembl chr 8:109,511,658...109,522,246

G

NDRG family member 4

decreases expression

Betaine results in decreased expression of NDRG4 mRNA

NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914

G

NFE2 like bZIP transcription factor 2

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA]; Betaine inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 protein]

PMID:37840533 PMID:38651543

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 12

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA

NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934

G

NLR family, pyrin domain containing 3

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of NLRP3 mRNA]

PMID:37840533 PMID:38651543

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nuclear protein 1, transcriptional regulator

decreases expression

Betaine results in decreased expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

8-oxoguanine DNA glycosylase

multiple interactions

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

Purkinje cell protein 4

increases expression

Betaine results in increased expression of PCP4 mRNA

NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725

G

phosphatidylcholine transfer protein

decreases expression

Betaine results in decreased expression of PCTP mRNA

NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867

G

period circadian regulator 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

PTEN induced kinase 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of PINK1 protein]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

DNA polymerase alpha 2, accessory subunit

decreases expression

Betaine results in decreased expression of POLA2 mRNA

NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348

G

DNA polymerase epsilon 2, accessory subunit

decreases expression

Betaine results in decreased expression of POLE2 mRNA

NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein
Betaine results in decreased expression of PPARA mRNA

PMID:20118189 PMID:22945834

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 1, regulatory subunit 3G

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA

NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525

G

protein phosphatase 2 catalytic subunit alpha

multiple interactions

Betaine inhibits the reaction [Ethanol results in decreased methylation of PPP2CA protein]

NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862

G

serine protease 23

increases expression

Betaine results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

serine protease 8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA

NCBI chr 1:182,536,229...182,540,745
Ensembl chr 1:182,536,229...182,540,815

G

presenilin 1

multiple interactions

Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

prostaglandin-endoperoxide synthase 1

decreases expression

Betaine results in decreased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

RAN binding protein 3-like

decreases expression

Betaine results in decreased expression of RANBP3L mRNA

NCBI chr 2:58,057,887...58,113,158
Ensembl chr 2:58,058,263...58,113,172

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein]

PMID:25559852 PMID:38651543

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulatory factor X4

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA

NCBI chr 7:18,853,065...19,015,378
Ensembl chr 7:18,853,322...19,014,967

G

regulator of G-protein signaling 16

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

regulator of G-protein signaling 2

increases expression

Betaine results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

ribonucleotide reductase regulatory subunit M2

decreases expression
multiple interactions

Betaine results in decreased expression of RRM2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA

PMID:26391144 PMID:33549593

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

S100 calcium binding protein A8

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

stearoyl-CoA desaturase

decreases expression

Betaine results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

secreted and transmembrane 1B

increases expression

Betaine results in increased expression of SECTM1A mRNA

NCBI chr10:106,324,070...106,333,779
Ensembl chr10:106,325,203...106,333,769

G

serine incorporator 2

decreases expression

Betaine results in decreased expression of SERINC2 mRNA

NCBI chr 5:142,592,308...142,614,628
Ensembl chr 5:142,592,309...142,618,364

G

serpin family A member 3N

decreases expression

Betaine results in decreased expression of SERPINA3N mRNA

NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433

G

solute carrier family 16, member 6

increases expression

Betaine results in increased expression of SLC16A6 mRNA

NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779

G

solute carrier family 22 member 5

multiple interactions

Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 25, member 30

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA

NCBI chr15:51,076,998...51,099,613
Ensembl chr15:51,077,002...51,099,613

G

solute carrier family 36 member 1

increases uptake

SLC36A1 protein results in increased uptake of Betaine

NCBI chr10:39,319,062...39,357,374
Ensembl chr10:39,324,337...39,354,217

G

solute carrier family 6 member 12

multiple interactions

Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA]

NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750

G

solute carrier family 6 member 20a

increases uptake

SLC6A20B protein results in increased uptake of Betaine

NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573

G

solute carrier family 6 member 9

decreases expression

Betaine results in decreased expression of SLC6A9 mRNA

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

sorting nexin 10

decreases expression

Betaine results in decreased expression of SNX10 mRNA

NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996

G

suppressor of cytokine signaling 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

sclerostin domain containing 1

increases expression

Betaine results in increased expression of SOSTDC1 mRNA

NCBI chr 6:53,051,336...53,055,510
Ensembl chr 6:53,051,354...53,055,579

G

SPC25 component of NDC80 kinetochore complex

decreases expression

Betaine results in decreased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

signal sequence receptor subunit 4

decreases expression

Betaine results in decreased expression of SSR4 mRNA

NCBI chr X:151,524,191...151,528,218
Ensembl chr X:151,524,009...151,528,202

G

signal transducer and activator of transcription 3

multiple interactions

Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

stathmin 1

decreases expression

Betaine results in decreased expression of STMN1 mRNA

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

syntaxin binding protein 1

decreases expression

Betaine results in decreased expression of STXBP1 mRNA

NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369

G

sulfotransferase family 1E member 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

TGF-beta activated kinase 1/MAP3K7 binding protein 1

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of TAB1 mRNA]

PMID:37840533 PMID:38651543

NCBI chr 7:111,675,829...111,707,058
Ensembl chr 7:111,686,371...111,707,058

G

transferrin receptor

multiple interactions

Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; Betaine inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein]

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

transforming growth factor, beta 2

increases expression

Betaine results in increased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

toll-like receptor 4

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]; Betaine inhibits the reaction [sodium arsenite results in increased expression of TNF protein]
Betaine inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]

PMID:22945834 PMID:36087182 PMID:37840533 PMID:38651543

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

Betaine inhibits the reaction [Doxorubicin results in increased phosphorylation of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tribbles pseudokinase 2

decreases expression

Betaine results in decreased expression of TRIB2 mRNA

NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370

G

unc-51 like autophagy activating kinase 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA

NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966

G

uroplakin 3B like 1

decreases expression

Betaine results in decreased expression of UPK3BL1 mRNA

NCBI chr12:20,610,353...20,616,366
Ensembl chr12:20,610,353...20,616,366

G

ubiquitin specific peptidase 2

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA

NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331

G

vanin 1

multiple interactions

[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

WNK lysine deficient protein kinase 4

decreases expression

Betaine results in decreased expression of WNK4 mRNA

NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829

G

Y box binding protein 2

decreases expression

Betaine results in decreased expression of YBX2 mRNA

NCBI chr10:54,659,719...54,665,371
Ensembl chr10:54,659,719...54,665,371

L-proline betaine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

interleukin 1 beta

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

matrix metallopeptidase 13

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 3

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

NFKB inhibitor alpha

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions

stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

meldonium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase, long chain

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

acyl-CoA dehydrogenase medium chain

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of ACADM mRNA

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

acyl-CoA dehydrogenase, very long chain

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACADVL mRNA

NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075

G

acyl-CoA oxidase 1

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

carnitine palmitoyltransferase 1B

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

carnitine palmitoyltransferase 1c

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of CPT1C mRNA

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

hexokinase 1

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of HK1 mRNA

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

pyruvate dehydrogenase kinase 1

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of PDK1 mRNA

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

peroxisome proliferator activated receptor alpha

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

PPARG coactivator 1 alpha

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of PPARGC1A mRNA

PMID:27559315 PMID:32389661

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PPARG coactivator 1 beta

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of PPARGC1B mRNA

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

solute carrier family 22 member 5

increases uptake

SLC22A5 protein results in increased uptake of 3-(2,2,2-trimethylhydrazine)propionate

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 2 member 4

increases expression

3-(2,2,2-trimethylhydrazine)propionate results in increased expression of SLC2A4 mRNA

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 5 member 2

affects expression

3-(2,2,2-trimethylhydrazine)propionate affects the expression of SLC5A2 mRNA

NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306

G

transcription factor A, mitochondrial

decreases expression

3-(2,2,2-trimethylhydrazine)propionate results in decreased expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

molsidomine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

frataxin

increases expression

Molsidomine results in increased expression of FXN mRNA

NCBI chr 1:221,874,007...221,897,543
Ensembl chr 1:221,872,420...221,897,540

G

prostaglandin I2 synthase

multiple interactions

Molsidomine inhibits the reaction [Hypoxia increases expression of Ptgis mRNA in the lung]

RGD

NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451

G

solute carrier family 22 member 1

multiple interactions

Molsidomine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 3

multiple interactions

Molsidomine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

N-methylnicotinate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

angiotensinogen

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

autophagy related 7

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

BCL2 associated X, apoptosis regulator

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein]
[trigonelline co-treated with Cisplatin] results in increased expression of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein

PMID:31935362 PMID:33148531

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein]
[trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein

PMID:31935362 PMID:33148531

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

beclin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in decreased expression of BECN1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

caspase 3

increases activity
multiple interactions

trigonelline results in increased activity of CASP3 protein
[trigonelline co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]

PMID:26593444 PMID:31935362 PMID:33148531

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CD36 molecule

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of CD36 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of CD36 protein]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

DNA-damage inducible transcript 3

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

epidermal growth factor

multiple interactions

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
trigonelline results in decreased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ferritin heavy chain 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

hexosaminidase subunit beta

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased secretion of HEXB protein]

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

heme oxygenase 1

decreases expression

trigonelline results in decreased expression of HMOX1 mRNA; trigonelline results in decreased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interleukin 1 beta

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]; trigonelline inhibits the reaction [INS2 protein affects the abundance of angiotensin I (1-7)]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

Kelch-like ECH-associated protein 1

multiple interactions

[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

leptin receptor

affects abundance

LEPR affects the abundance of trigonelline

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
trigonelline results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
trigonelline results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

mechanistic target of rapamycin kinase

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

trigonelline results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases phosphorylation

trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]
trigonelline results in decreased phosphorylation of NFE2L2 protein

PMID:24015256 PMID:29211853 PMID:29959986 PMID:33148531

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
decreases expression

trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]
trigonelline results in decreased expression of NQO1 mRNA; trigonelline results in decreased expression of NQO1 protein

PMID:24015256 PMID:29959986 PMID:33148531

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

poly (ADP-ribose) polymerase 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased cleavage of PARP1 protein]
[trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein

PMID:30208301 PMID:33148531

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phospholipase C, gamma 1

multiple interactions

trigonelline inhibits the reaction [iodixanol results in increased phosphorylation of PLCG1 protein]

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

perilipin 1

multiple interactions

trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PLIN1 protein]

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of PPARG protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

sequestosome 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SQSTM1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

O-acetyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

apurinic/apyrimidinic endodeoxyribonuclease 1

increases expression

Acetylcarnitine results in increased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

ATPase H+ transporting V1 subunit F

increases expression

Acetylcarnitine results in increased expression of ATP6V1F mRNA

NCBI chr 4:58,067,666...58,070,628

G

complement C1q A chain

decreases expression

Acetylcarnitine results in decreased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C4B

decreases expression

Acetylcarnitine results in decreased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

caspase 3

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA]

PMID:20067779 PMID:29278859

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA]

PMID:20067779 PMID:26349760 PMID:29278859

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

citrate synthase

decreases activity

Acetylcarnitine results in decreased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cathepsin S

decreases expression

Acetylcarnitine results in decreased expression of CTSS mRNA

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

C-X-C motif chemokine ligand 14

decreases expression

Acetylcarnitine results in decreased expression of CXCL14 mRNA

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

early growth response 1

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

glial fibrillary acidic protein

decreases expression

Acetylcarnitine results in decreased expression of GFAP mRNA

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutathione-disulfide reductase

multiple interactions

Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase pi 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

heme oxygenase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA]

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

heat shock protein family B (small) member 1

decreases expression

Acetylcarnitine results in decreased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of Acetylcarnitine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 1 beta

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

microsomal glutathione S-transferase 1

increases expression

Acetylcarnitine results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

nerve growth factor

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 1

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

multiple interactions

Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

phenylalanine hydroxylase

decreases expression

Acetylcarnitine results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

PTEN induced kinase 1

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Acetylcarnitine results in increased expression of PPARGC1A protein
[Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN]

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

proteasome 20S subunit beta 6

increases expression

Acetylcarnitine results in increased expression of PSMB6 mRNA

NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586

G

prothymosin alpha

increases expression

Acetylcarnitine results in increased expression of PTMA mRNA

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S17

increases expression

Acetylcarnitine results in increased expression of RPS17 mRNA

NCBI chr 1:135,295,920...135,298,506
Ensembl chr 1:135,295,919...135,298,535
Ensembl chr 8:135,295,919...135,298,535

G

src kinase associated phosphoprotein 2

decreases expression

Acetylcarnitine results in decreased expression of SKAP2 mRNA

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891

G

solute carrier family 25 member 20

multiple interactions

Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

synuclein alpha

multiple interactions

[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

troponin I3, cardiac type

multiple interactions

Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein]

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

O-butanoyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

O-octanoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

carnitine O-octanoyltransferase

increases chemical synthesis

CROT protein results in increased chemical synthesis of octanoylcarnitine

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

O-palmitoylcarnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

glutaminase

increases chemical synthesis

GLS protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

protein phosphatase 3, regulatory subunit B, alpha

decreases metabolic processing

PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine

NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907

G

protein kinase AMP-activated catalytic subunit alpha 1

increases chemical synthesis

PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

O-propanoyl-L-carnitine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

increases abundance
multiple interactions

APP protein mutant form results in increased abundance of propionylcarnitine
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of propionylcarnitine]
[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

microtubule-associated protein tau

decreases abundance
multiple interactions

MAPT protein mutant form results in decreased abundance of propionylcarnitine
PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of propionylcarnitine]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

presenilin 1

multiple interactions

[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

perifosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation

[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein]
perifosine results in decreased phosphorylation of AKT1 protein
[perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein

PMID:15781658 PMID:21267448 PMID:30265530 PMID:31445927

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2-antagonist/killer 1

multiple interactions

[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions

[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

caspase 3

multiple interactions
decreases expression

[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein
perifosine results in decreased expression of CASP3 protein

PMID:15781658 PMID:25416439

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression

[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with Vorinostat] results in increased activity of CASP8 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]

PMID:15781658 PMID:32587277

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

perifosine inhibits the reaction [Mitomycin results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cytochrome c, somatic

multiple interactions

[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

epidermal growth factor

multiple interactions

perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

Fas cell surface death receptor

affects response to substance

perifosine affects the susceptibility to FAS protein

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

forkhead box O1

multiple interactions

[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA
perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]

PMID:30265530 PMID:33078829

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

galactosidase, beta 1

multiple interactions

perifosine inhibits the reaction [Mitomycin results in increased activity of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

linker for activation of T cells family, member 2

multiple interactions
decreases response to substance
decreases expression

ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]
LAT2 protein results in decreased susceptibility to perifosine

PMID:23001822 PMID:32587277

NCBI chr12:22,104,173...22,118,294
Ensembl chr12:22,104,219...22,118,288

G

mitogen activated protein kinase kinase 1

multiple interactions

MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase 1

multiple interactions

[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mechanistic target of rapamycin kinase

multiple interactions

[perifosine co-treated with temsirolimus] results in decreased activity of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

tumor necrosis factor

increases response to substance

perifosine results in increased susceptibility to TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

phosphatidylcholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases secretion

ABCB11 protein results in increased secretion of Phosphatidylcholines

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects export
affects transport

ABCB1 protein affects the export of Phosphatidylcholines
ABCB1 protein affects the transport of Phosphatidylcholines

PMID:11147995 PMID:11745043

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

affects transport
affects export

ABCB4 protein affects the transport of Phosphatidylcholines
ABCB4 protein affects the export of Phosphatidylcholines

PMID:11745043 PMID:15696852

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

acetyl-CoA acetyltransferase 1

decreases activity

Phosphatidylcholines results in decreased activity of ACAT1 protein

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

adiponectin, C1Q and collagen domain containing

decreases expression

Phosphatidylcholines results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

aryl hydrocarbon receptor

multiple interactions
increases abundance

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

amyloid beta precursor protein

multiple interactions

[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arsenite methyltransferase

affects metabolic processing

AS3MT gene mutant form affects the metabolism of Phosphatidylcholines

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

BCL2 associated X, apoptosis regulator

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

caspase 3

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

increases expression

Phosphatidylcholines results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

multiple interactions

Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin dependent kinase 2

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

carboxylesterase 1D

decreases expression

Phosphatidylcholines results in decreased expression of CES1D mRNA

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

collagen type I alpha 1 chain

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

C-reactive protein

affects binding
decreases activity

CRP protein binds to Phosphatidylcholines
Phosphatidylcholines results in decreased activity of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects activity

Phosphatidylcholines affects the activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450 family 7 subfamily A member 1

increases activity

Phosphatidylcholines results in increased activity of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

ectonucleotide pyrophosphatase/phosphodiesterase 7

increases hydrolysis

ENPP7 protein results in increased hydrolysis of Phosphatidylcholines

NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589

G

fatty acid synthase

multiple interactions

[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

decreases abundance

FGF19 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glutathione peroxidase 4

multiple interactions

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases activity

Phosphatidylcholines results in increased activity of HMGCR protein

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

insulin-like growth factor 1

increases degradation

IGF1 protein results in increased degradation of Phosphatidylcholines

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 10

increases expression

Phosphatidylcholines results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
multiple interactions

Phosphatidylcholines results in increased expression of IL1B mRNA
Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein

PMID:23911798 PMID:30958839

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression

Phosphatidylcholines results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin

decreases expression

Phosphatidylcholines results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase C, hepatic type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPC gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipase E, hormone sensitive type

increases expression

Phosphatidylcholines results in increased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lipase G, endothelial type

multiple interactions
increases abundance

[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines
LIPG gene mutant form results in increased abundance of Phosphatidylcholines

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lactotransferrin

multiple interactions

[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795

G

matrix metallopeptidase 2

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

NADPH oxidase 4

multiple interactions

NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

nuclear receptor subfamily 0, group B, member 2

decreases abundance

NR0B2 protein results in decreased abundance of Phosphatidylcholines

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326

G

platelet-activating factor acetylhydrolase 1b, regulatory subunit 1

multiple interactions
increases secretion

PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines]
PAFAH1B1 protein results in increased secretion of Phosphatidylcholines

NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808

G

platelet-activating factor acetylhydrolase 2

multiple interactions

PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]

NCBI chr 5:146,607,050...146,636,203
Ensembl chr 5:146,613,498...146,634,943

G

phosphate cytidylyltransferase 1A, choline

multiple interactions

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357

G

phosphatidylethanolamine N-methyltransferase

multiple interactions

PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

perilipin 1

increases expression

Phosphatidylcholines results in increased expression of PLIN1 mRNA

NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828

G

phospholipid phosphatase 6

multiple interactions
increases chemical synthesis

PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]

NCBI chr 1:226,679,100...226,681,952
Ensembl chr 1:226,679,100...226,681,949

G

patatin-like phospholipase domain containing 2

decreases expression

Phosphatidylcholines results in decreased expression of PNPLA2 mRNA

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

patatin-like phospholipase domain containing 6

affects abundance

PNPLA6 protein affects the abundance of Phosphatidylcholines

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734

G

paraoxonase 2

increases activity
increases expression

Phosphatidylcholines results in increased activity of PON2 protein
Phosphatidylcholines results in increased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

paraoxonase 3

multiple interactions

Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]

NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855

G

peroxisome proliferator-activated receptor gamma

increases expression

Phosphatidylcholines results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 beta

increases abundance

PPARGC1B results in increased abundance of Phosphatidylcholines

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194

G

phosphatase and tensin homolog

affects binding
multiple interactions

PTEN protein binds to Phosphatidylcholines
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

resistin

decreases expression

Phosphatidylcholines results in decreased expression of RETN mRNA

NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620

G

surfactant protein A1

multiple interactions

[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]

NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685

G

transforming growth factor, beta 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
increases expression
increases abundance

GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
Phosphatidylcholines results in increased expression of TNF mRNA
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein

PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin 1

multiple interactions

[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

pyocyanine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

increases expression
multiple interactions

Pyocyanine results in increased expression of AHR mRNA
Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter]

PMID:28476168 PMID:31078726

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

activating transcription factor 6

increases activity

Pyocyanine results in increased activity of ATF6 protein

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

C-C motif chemokine ligand 5

decreases expression

Pyocyanine results in decreased expression of CCL5 mRNA; Pyocyanine results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

catenin beta 1

increases expression

Pyocyanine results in increased expression of CTNNB1 mRNA

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Pyocyanine results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

epidermal growth factor receptor

increases phosphorylation

Pyocyanine results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

fatty acid binding protein 4

decreases expression

Pyocyanine results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Pyocyanine results in increased expression of GCLC mRNA
[Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

heat shock transcription factor 1

increases activity

Pyocyanine results in increased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 10

increases expression

Pyocyanine results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

decreases expression

Pyocyanine results in decreased expression of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 6

increases expression

Pyocyanine results in increased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

mitogen activated protein kinase kinase 1

increases phosphorylation

Pyocyanine results in increased phosphorylation of MAP2K1 protein

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

increases phosphorylation

Pyocyanine results in increased phosphorylation of MAP2K2 protein

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]

PMID:24015256 PMID:24316274

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

Pyocyanine results in increased phosphorylation of MAPK3 protein
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]

PMID:24015256 PMID:24316274

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases activity

1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein]
Pyocyanine results in increased activity of NFE2L2 protein

PMID:24015256 PMID:27613716

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Pyocyanine results in increased expression of NQO1 mRNA
[Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

peroxisome proliferator-activated receptor gamma

decreases expression

Pyocyanine results in decreased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

TAR DNA binding protein

multiple interactions

Pyocyanine promotes the reaction [AHR protein binds to TARDBP promoter]

NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055

G

tumor necrosis factor

increases expression

Pyocyanine results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

S-adenosyl-L-methioninate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adhesion G protein-coupled receptor E4

decreases expression

S-Adenosylmethionine results in decreased expression of ADGRE4 mRNA

NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760

G

adhesion G protein-coupled receptor E5

decreases expression

S-Adenosylmethionine results in decreased expression of ADGRE5 mRNA

NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638

G

alpha-fetoprotein

multiple interactions
decreases expression

S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of AFP mRNA]
S-Adenosylmethionine results in decreased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

aryl hydrocarbon receptor

decreases abundance
multiple interactions

AHR protein results in decreased abundance of S-Adenosylmethionine
PEMT protein promotes the reaction [AHR protein results in decreased abundance of S-Adenosylmethionine]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aminolevulinate dehydratase

increases activity

S-Adenosylmethionine results in increased activity of ALAD protein

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

5'-aminolevulinate synthase 2

multiple interactions

[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]

NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519

G

amyloid beta precursor protein

increases secretion

S-Adenosylmethionine results in increased secretion of APP protein modified form

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arsenite methyltransferase

multiple interactions
affects binding

Cysteine promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]; Glutathione promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]; S-Adenosylmethionine promotes the reaction [AS3MT protein binds to and results in increased methylation of arsenite]; tris(2-carboxyethyl)phosphine promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]

PMID:22955273 PMID:24124590 PMID:25349987

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

activating transcription factor 3

increases expression

S-Adenosylmethionine results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

ATPase copper transporting beta

multiple interactions

ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

betaine-homocysteine S-methyltransferase 2

multiple interactions

S-Adenosylmethionine inhibits the reaction [BHMT2 protein results in increased metabolism of Vitamin U]

NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475

G

caspase 12

decreases expression

S-Adenosylmethionine results in decreased expression of CASP12 mRNA

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 3

multiple interactions
decreases activity

S-Adenosylmethionine inhibits the reaction [Ethanol results in increased activity of CASP3 protein]
S-Adenosylmethionine results in decreased activity of CASP3 protein

PMID:17869084 PMID:18571630

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 1

multiple interactions

S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased expression of CCN1 protein]; S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased stability of CCN1 mRNA]

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cadherin 2

multiple interactions

S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased expression of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

collagen type I alpha 1 chain

decreases expression
multiple interactions

S-Adenosylmethionine results in decreased expression of COL1A1 mRNA
S-Adenosylmethionine inhibits the reaction [LEP protein results in increased expression of COL1A1 mRNA]

PMID:15983038 PMID:16996477

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions
decreases expression

S-Adenosylmethionine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA]; S-Adenosylmethionine inhibits the reaction [SP1 protein binds to COL1A2 promoter]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein binds to COL1A2 promoter]
S-Adenosylmethionine results in decreased expression of COL1A2 mRNA

PMID:8878782 PMID:15983038

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

catechol-O-methyltransferase

multiple interactions

[tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of S-Adenosylmethionine]

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cytochrome c, somatic

multiple interactions

S-Adenosylmethionine inhibits the reaction [Acetaminophen affects the localization of CYCS protein]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
multiple interactions

S-Adenosylmethionine results in decreased activity of CYP2E1 protein
S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of 4-nitrophenol]; S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of Dimethylnitrosamine]; S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of Ethanol]
S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased expression of CYP2E1 protein]; S-Adenosylmethionine promotes the reaction [Carbon Tetrachloride results in decreased expression of and results in decreased activity of CYP2E1 protein]

PMID:15763544 PMID:15983038 PMID:22683606

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

dopa decarboxylase

multiple interactions

[Levodopa co-treated with DDC] results in increased abundance of S-Adenosylmethionine

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

discs large MAGUK scaffold protein 4

multiple interactions

S-Adenosylmethionine inhibits the reaction [Particulate Matter results in decreased expression of DLG4 protein]

NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153

G

DNA methyltransferase 1

multiple interactions

S-Adenosylmethionine inhibits the reaction [arsenic trioxide inhibits the reaction [DNMT1 protein binds to ESR1 promoter]]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased expression of DNMT1 protein]

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 alpha

multiple interactions

S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased expression of DNMT3A protein]
S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of DNMT3A mRNA]

PMID:18098314 PMID:22558281

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

early growth response 1

multiple interactions

[S-Adenosylmethionine co-treated with Arsenic] affects the expression of EGR1 mRNA; [S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of EGR1 promoter]] which results in decreased expression of EGR1 mRNA; S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of EGR1 promoter]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

estrogen receptor 1

multiple interactions

S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of GREB1 mRNA]; S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of TFF1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide inhibits the reaction [DNMT1 protein binds to ESR1 promoter]]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased methylation of ESR1 promoter]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of ESR1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of ESR1 protein]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

Fc gamma receptor 1A

decreases expression

S-Adenosylmethionine results in decreased expression of FCGR1 mRNA

NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994

G

fibroblast growth factor 19

increases abundance

FGF19 protein results in increased abundance of S-Adenosylmethionine

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

fibrinogen-like 2

decreases expression

S-Adenosylmethionine results in decreased expression of FGL2 mRNA

NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207

G

guanylate binding protein 2

decreases expression

S-Adenosylmethionine results in decreased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

growth regulating estrogen receptor binding 1

multiple interactions

S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of GREB1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of GREB1 mRNA]

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

glutathione-disulfide reductase

multiple interactions

S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione synthetase

multiple interactions

S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]]

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase mu 2

multiple interactions

S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of GSTM2 mRNA]

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

heart and neural crest derivatives expressed 2

multiple interactions

[Progesterone co-treated with S-Adenosylmethionine] results in increased methylation of HAND2 promoter; S-Adenosylmethionine inhibits the reaction [Progesterone results in increased expression of HAND2 mRNA]

NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891

G

hemoglobin subunit beta

multiple interactions

[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

histone deacetylase 9

multiple interactions

S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of HDAC9 mRNA]

NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333

G

hydroxymethylbilane synthase

multiple interactions

[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]

NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957

G

interferon-induced protein 44-like

decreases expression

S-Adenosylmethionine results in decreased expression of IFI44L mRNA

NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359

G

interferon gamma

multiple interactions

S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of IL1B protein]
S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA]

PMID:17080400 PMID:19822164

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 2 receptor subunit gamma

decreases expression

S-Adenosylmethionine results in decreased expression of IL2RG mRNA

NCBI chr X:66,395,330...66,399,026
Ensembl chr X:66,392,542...66,399,823

G

interleukin 36, gamma

decreases expression

S-Adenosylmethionine results in decreased expression of IL36G mRNA

NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480

G

interleukin 6

multiple interactions

S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein]
S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA]

PMID:17080400 PMID:19822164

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KLF transcription factor 6

decreases expression
multiple interactions

S-Adenosylmethionine results in decreased expression of KLF6 mRNA
S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of KLF6 mRNA]

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

leptin

multiple interactions

S-Adenosylmethionine inhibits the reaction [LEP protein results in increased expression of COL1A1 mRNA]; S-Adenosylmethionine inhibits the reaction [Vitamin K 3 results in increased expression of LEP mRNA]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lymphotoxin beta

multiple interactions

S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA]

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

MAF bZIP transcription factor

multiple interactions

S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]]

NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365

G

MAF bZIP transcription factor G

multiple interactions

S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]]

NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026

G

mitogen activated protein kinase 1

multiple interactions

S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK1 protein]
[1,2-linoleoylphosphatidylcholine co-treated with S-Adenosylmethionine] inhibits the reaction [Vitamin K 3 results in increased phosphorylation of MAPK1 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK1 protein modified form]]

PMID:15983038 PMID:16996477

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK3 protein]
[1,2-linoleoylphosphatidylcholine co-treated with S-Adenosylmethionine] inhibits the reaction [Vitamin K 3 results in increased phosphorylation of MAPK3 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK3 protein modified form]]

PMID:15983038 PMID:16996477

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

methionine adenosyltransferase 1A

affects abundance
increases chemical synthesis

MAT1A affects the abundance of S-Adenosylmethionine
MAT1A protein results in increased chemical synthesis of S-Adenosylmethionine

PMID:8373829 PMID:12060674

NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274

G

methionine adenosyltransferase 2A

increases chemical synthesis

MAT2A protein results in increased chemical synthesis of S-Adenosylmethionine

NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493

G

methyl-CpG binding domain protein 2

multiple interactions

S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of MBD2 protein]

NCBI chr18:64,174,002...64,240,795
Ensembl chr18:64,174,002...64,240,794

G

maternally expressed 3

multiple interactions

S-Adenosylmethionine inhibits the reaction [Arsenicals results in increased expression of MEG3 mRNA]

NCBI chr 6:128,491,808...128,524,010